drugset / Trial / NCT05116709
Assessment of Safety and Preliminary Clinical Efficacy with BAT6005 in Advanced Malignant Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This research design for center, increasing openness, dose and dose extension phase I clinical trials, research the main evaluation BAT6005 injection single drug in patients with advanced malignant solid tumors in the safety, tolerability and PK characteristics, to explore the maximum tolerated dose and preliminary antitumor efficacy, provide the basis for subsequent clinical trials recommended dose. Part I: single drug dose escalation study. Part TWO: dose extension study.
Timeline
- Start
- 2021-11-12
- Primary completion
- 2024-01-10
- Completion
- 2024-09-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAT6005 | Monoclonal antibody | 10 mg | — |
| Subject | BAT6005 | Monoclonal antibody | 30 mg | — |
| Subject | BAT6005 | Monoclonal antibody | 100 mg | — |
| Subject | BAT6005 | Monoclonal antibody | 300 mg | — |
| Subject | BAT6005 | Monoclonal antibody | 600 mg | — |
| Subject | BAT6005 | Monoclonal antibody | 900 mg | — |
Indications
No indication recorded.